한국어
Quantus

ImmuneOncia

424870 · KOSDAQ
₩2,890+3.03%
2026-09-04 close

ImmuneOncia last closed at ₩2,890 (+3.03%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -10.65
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-10.65
Beneish M-Score
—

Statistical flag unavailable

Sloan accrual
34.27%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

0/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score0/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -2240%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-1,924.8%
Interest coverage
-1,819.2x
Return on equity (ROE)
-29.3%

Operating margin −5pp

Operating loss
Interest coverageBase -1,819.2x adverse case -1,823.9x
Return on equity (ROE)Base -29.3% adverse case -65.1%

Revenue −15%

Interest coverage risk
Interest coverageBase -1,819.2x adverse case -1,546.3x
Return on equity (ROE)Base -29.3% adverse case -55.2%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -1,819.2x adverse case -88.5x
Return on equity (ROE)Base -29.3% adverse case -65.6%

Interest coverage limit

Already below the limit by 1,925.9pp

Interest coverage limit at an operating margin of 1.1%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-18

Suppliers disclosed by the company in its 2026-03-18 annual report.

Suppliers without disclosed amount

CROUSDGBPEURCHF

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 유한양행57.23%2026-05-27 · 증감 -10.14%p

Connections

AI-extracted related companies · for reference

Customers
AstellasBoehringer Ingelheim
🔗 See in the full market map →

Recent filings

ImmuneOncia's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About ImmuneOncia
What technical signals does ImmuneOncia (424870) have?
ImmuneOncia current technical signals: no active technical signal.
Is ImmuneOncia a cup-and-handle pattern?
No. ImmuneOncia has no valid cup-and-handle signal right now.
What are ImmuneOncia's financials and valuation?
ImmuneOncia's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy